Cingulate Inc - חוב לטווח קצר של החברה CING

The evolution of short-term debt for Cingulate Inc. (CING) demonstrates liability dynamics, where the 0.01 mark indicates the current state. Cingulate Inc. is preparing to bring extended-release formulations for ADHD therapy to market. Development is underway in Kansas, while mass production has been outsourced to external CDMO partners. However, liquidity shortages and dependence on test outcomes create significant financial risks.

This indicator aggregates all obligations with maturities of up to one year, determining current solvency and default risk in the event of a liquidity shortage. For Cingulate Inc. (CING), with its fixed R&D expenditures, short-term accounts payable serves as a marker of financial viability until the commercialization of drugs, where a reduction in debt on the chart confirms the company's resilience before entering the high-margin production stage.